Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
 
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2018, Vol. 9 Issue (1) : 17-30     DOI: 10.14336/AD.2017.0230
Orginal Article |
PARP-1 Inhibition Rescues Short Lifespan in Hyperglycemic C. Elegans And Improves GLP-1 Secretion in Human Cells
Xia Qianghua1, Lu Sumei1, Ostrovsky Julian1, McCormack Shana E2,3,4, Falk Marni J1,3, Grant Struan F. A1,2,3,4,*
1Division of Human Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.
2Division of Endocrinology and Diabetes, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.
3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
4Institute of Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Download: PDF(1317 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    
Abstract  

TCF7L2 is located at one of the most strongly associated type 2 diabetes loci reported to date. We previously reported that the most abundant member of a specific protein complex to bind across the presumed causal variant at this locus, rs7903146, was poly [ADP-ribose] polymerase type 1 (PARP-1). We analyzed the impact of PARP-1 inhibition on C. elegans health in the setting of hyperglycemia and on glucose-stimulated GLP-1 secretion in human intestinal cells. Given that high glucose concentrations progressively shorten the lifespan of C. elegans, in part by impacting key well-conserved insulin-modulated signaling pathways, we investigated the effect of PARP-1 inhibition with Olaparib on the lifespan of C. elegans nematodes under varying hyperglycemic conditions. Subsequently, we investigated whether Olaparib treatment had any effect on glucose-stimulated GLP-1 secretion in the human NCI-H716 intestinal cell line, a model system for the investigation of enteroendocrine function. Treatment with 100uM Olaparib in nematodes exposed to high concentrations of glucose led to significant lifespan rescue. The beneficial lifespan effect of Olaparib appeared to require both PARP-1 and TCF7L2, since treatment had no effect in hyperglycemic conditions in knock-out worm strains for either of these homologs. Further investigation using the NCI-H716 cells revealed that Olaparib significantly enhanced secretion of the incretin, GLP-1, plus the gene expression of TCF7L2, GCG and PC1. These data from studies in both C. elegans and a human cell line suggest that PARP-1 inhibition offers a novel therapeutic avenue to treat type 2 diabetes.

Keywords TCF7L2      PARP-1      glucose      GLP-1      C. elegans     
Corresponding Authors: Grant Struan F. A   
About author:

These authors contributed equally to this work

Issue Date: 01 February 2018
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Xia Qianghua
Lu Sumei
Ostrovsky Julian
McCormack Shana E
Falk Marni J
Grant Struan F. A
Cite this article:   
Xia Qianghua,Lu Sumei,Ostrovsky Julian, et al. PARP-1 Inhibition Rescues Short Lifespan in Hyperglycemic C. Elegans And Improves GLP-1 Secretion in Human Cells[J]. Aging and disease, 2018, 9(1): 17-30.
URL:  
http://www.aginganddisease.org/EN/10.14336/AD.2017.0230     OR     http://www.aginganddisease.org/EN/Y2018/V9/I1/17
Figure 1.  High glucose conditions shorten <i>C. elegans</i> lifespan

Wild-type N2 C. elegans cultured under standard and high glucose conditions and subsequent lifespan assays. (A) Determination of lifespan for N2 worms unexposed or exposed to 16 mM glucose (P<0.002, log-rank test, n=100); (B) Determination of lifespan for N2 worms unexposed or exposed to 25 mM glucose (P<0.0001, log-rank test, n=100).

Figure 2.  The lifespan-shortening effects of high glucose reduced by Olaparib treatment

(A) Determination of lifespan for N2 worms exposed to 16 mM glucose together with 100 uM or 0 µM Olaparib (P<0.0001, log-rank test, n=100); (B) Determination of lifespan for N2 worms exposed to 25 mM glucose together with 100 uM or 0 µM Olaparib (P<0.05, log-rank test, n=100).

Figure 3.  The beneficial effect of Olaparib treatment on <i>C. elegans</i> lifespan in the setting of high glucose was target-specific and dependent on the PARP-1 related signaling pathway

(A) Determination of lifespan for PARP-1 homolog, pme-1, worms exposed to 16 mM glucose together with 100 µM or without Olaparib (P>0.05, log-rank test, n=100); (B) Determination of lifespan for pme-1 worms exposed to 25 mM glucose together with 100 µM or 0 µM Olaparib (P>0.05, log-rank test, n=100).

Figure 4.  <i>TCF7L2</i> homolog, <i>pop-1</i>, is required for the beneficial effect in the setting of high glucose of Olaparib treatment on lifespan

(A) Determination of lifespan for N2 worms fed with HT115 feeding strain containing the pL4440 empty vector and exposed to 16 mM glucose with 100 µM or 0 uM Olaparib (P<0.03, log-rank test, n=100); (B) Determination of lifespan for N2 worms fed with HT115 feeding strain containing the pL4440 pL4440/pop-1 RNAi and exposed to 16 mM glucose with 100uM or 0 µM Olaparib (P>0.05, log-rank test, n=100).

Figure 5.  Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells

Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.

Figure 6.  Olaparib treatment of endoendocrine intestinal cells increases expression of (A)<i>TCF7L2</i>, (B)<i>GCG</i> and (C)<i>PC1</i>

Relative levels of individual gene expression in the control and the Olaparib treatment groups determined by quantitative PCR with GAPDH normalization. Values are the mean of three independent experiments. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05 or **P<0.01.

Figure 7.  Integrated model to define the role of PARP-1 inhibition in the type 2 diabetes related pathway

Olaparib treatment increases the expression of TCF7L2, GCG and PC1, thereby enhancing GLP-1 secretion in the endoendocrine L type gastrointestinal cells and subsequently promoting insulin secretion in the pancreatic β-cell.

[1] Lee SJ, Murphy CT, Kenyon C (2009). Glucose shortens the life span of C. elegans by downregulating DAF-16/FOXO activity and aquaporin gene expression. Cell Metab, 10:379-391.
[2] Finch CE, Ruvkun G (2001). The genetics of aging. Annu Rev Genomics Hum Genet, 2:435-462.
[3] Visscher PM, Brown MA, McCarthy MI, Yang J (2012). Five years of GWAS discovery. Am J Hum Genet, 90:7-24.
[4] Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J,et al. (2006). Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet, 38:320-323.
[5] DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium (2014). Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet, 46:234-244.
[6] Wellcome Trust Case Control C, Maller JB, McVean G, Byrnes J, Vukcevic D, Palin K,et al. (2012). Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet, 44:1294-1301.
[7] MacDonald BT, Tamai K, He X (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell, 17:9-26.
[8] Pearson ER (2009). Translating TCF7L2: from gene to function. Diabetologia, 52:1227-1230.
[9] Ni Z, Anini Y, Fang X, Mills G, Brubaker PL, Jin T (2003). Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J Biol Chem, 278:1380-1387.
[10] Langley AK, Suffoletta TJ, Jennings HR (2007). Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy, 27:1163-1180.
[11] Drucker DJ, Nauck MA (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368:1696-1705.
[12] Xia Q, Deliard S, Yuan CX, Johnson ME, Grant SF (2015). Characterization of the transcriptional machinery bound across the widely presumed type 2 diabetes causal variant, rs7903146, within TCF7L2. Eur J Hum Genet, 23:103-109.
[13] Li G, Cunin P, Wu D, Diogo D, Yang Y, Okada Y,et al. (2016). The Rheumatoid Arthritis Risk Variant CCR6DNP Regulates CCR6 via PARP-1. PLoS Genet, 12:e1006292.
[14] Krishnakumar R, Kraus WL (2010). PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol Cell, 39:736-749.
[15] Gong L, Liu FQ, Wang Y, Hou XG, Zhang W, Qin WD,et al. (2012). Poly (ADP-ribose) transferase/polymerase-1-deficient mice resistant to age-dependent decrease in beta-cell proliferation. Mol Med, 18:816-824.
[16] Idogawa M, Yamada T, Honda K, Sato S, Imai K, Hirohashi S (2005). Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. Gastroenterology, 128:1919-1936.
[17] Idogawa M, Masutani M, Shitashige M, Honda K, Tokino T, Shinomura Y,et al. (2007). Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate beta-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling. Cancer Res, 67:911-918.
[18] Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S,et al. (1999). Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A, 96:3059-3064.
[19] Li B, Luo C, Chowdhury S, Gao ZH, Liu JL (2013). Parp1 deficient mice are protected from streptozotocin-induced diabetes but not caerulein-induced pancreatitis, independent of the induction of Reg family genes. Regul Pept, 186:83-91.
[20] Dingley S, Polyak E, Lightfoot R, Ostrovsky J, Rao M, Greco T,et al. (2010). Mitochondrial respiratory chain dysfunction variably increases oxidant stress in Caenorhabditis elegans. Mitochondrion, 10:125-136.
[21] Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow M (2007). Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab, 6:280-293.
[22] Schlotterer A, Kukudov G, Bozorgmehr F, Hutter H, Du X, Oikonomou D,et al. (2009). C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes, 58:2450-2456.
[23] Kenyon CJ (2010). The genetics of ageing. Nature, 464:504-512.
[24] van Heemst D, Beekman M, Mooijaart SP, Heijmans BT, Brandt BW, Zwaan BJ,et al. (2005). Reduced insulin/IGF-1 signalling and human longevity. Aging Cell, 4:79-85.
[25] Reimer RA, Darimont C, Gremlich S, Nicolas-Metral V, Ruegg UT, Mace K (2001). A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology, 142:4522-4528.
[26] Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C,et al. (2003). Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest, 112:1049-1057.
[27] Caldecott KW (2007). Mammalian single-strand break repair: mechanisms and links with chromatin. DNA Repair (Amst), 6:443-453.
[28] Woodhouse BC, Dianov GL (2008). Poly ADP-ribose polymerase-1: an international molecule of mystery. DNA Repair (Amst), 7:1077-1086.
[29] Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010). PARP inhibition: PARP1 and beyond. Nat Rev Cancer, 10:293-301.
[30] Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T,et al. (2012). Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs, 21:1575-1584.
[31] Glendenning J, Tutt A (2011). PARP inhibitors--current status and the walk towards early breast cancer. Breast, 20 Suppl 3:S12-19.
[32] Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G,et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med, 366:1382-1392.
[33] Uchigata Y, Yamamoto H, Nagai H, Okamoto H (1983). Effect of poly(ADP-ribose) synthetase inhibitor administration to rats before and after injection of alloxan and streptozotocin on islet proinsulin synthesis. Diabetes, 32:316-318.
[34] Dooley J, Tian L, Schonefeldt S, Delghingaro-Augusto V, Garcia-Perez JE, Pasciuto E,et al. (2016). Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes. Nat Genet, 48:519-527.
[35] Consortium CeS (1998). Genome sequence of the nematode C. elegans: a platform for investigating biology. Science, 282:2012-2018.
[36] Sonnhammer EL, Durbin R (1997). Analysis of protein domain families in Caenorhabditis elegans. Genomics, 46:200-216.
[37] Lai CH, Chou CY, Ch’ang LY, Liu CS, Lin W (2000). Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. Genome Res, 10:703-713.
[38] Kuwabara PE, O’Neil N (2001). The use of functional genomics in C. elegans for studying human development and disease. J Inherit Metab Dis, 24:127-138.
[39] Harris TW, Chen N, Cunningham F, Tello-Ruiz M, Antoshechkin I, Bastiani C,et al. (2004). WormBase: a multi-species resource for nematode biology and genomics. Nucleic Acids Res, 32:D411-417.
[40] Yokoyama K, Fukumoto K, Murakami T, Harada S, Hosono R, Wadhwa R,et al. (2002). Extended longevity of Caenorhabditis elegans by knocking in extra copies of hsp70F, a homolog of mot-2 (mortalin)/mthsp70/Grp75. FEBS Lett, 516:53-57.
[41] Urban N, Tsitsipatis D, Gille A, Hamann I, Hou X, Klotz LO (2014). Modulation of cellular thiol status affects FoxO activity and life span. Free Radic Biol Med, 75 Suppl 1:S53.
[42] Hamilton B, Dong Y, Shindo M, Liu W, Odell I, Ruvkun G,et al. (2005). A systematic RNAi screen for longevity genes in C. elegans. Genes Dev, 19:1544-1555.
[43] Lee SS, Lee RY, Fraser AG, Kamath RS, Ahringer J, Ruvkun G (2003). A systematic RNAi screen identifies a critical role for mitochondria in C. elegans longevity. Nat Genet, 33:40-48.
[44] Scopsi L, Gullo M, Rilke F, Martin S, Steiner DF (1995). Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation. J Clin Endocrinol Metab, 80:294-301.
[45] Donnelly D (2012). The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol, 166:27-41.
[46] Ahren B (2011). GLP-1 for type 2 diabetes. Exp Cell Res, 317:1239-1245.
[47] Yi F, Brubaker PL, Jin T (2005). TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem, 280:1457-1464.
[48] Zhou Y, Oskolkov N, Shcherbina L, Ratti J, Kock KH, Su J,et al. (2016). HMGB1 binds to the rs7903146 locus in TCF7L2 in human pancreatic islets. Mol Cell Endocrinol, 430:138-145.
[49] Gaulton KJ, Ferreira T, Lee Y, Raimondo A, Magi R, Reschen ME,et al. (2015). Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet, 47:1415-1425.
[50] Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI,et al. (2015). Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet, 47:1294-1303.
[51] Xia Q, Chesi A, Manduchi E, Johnston BT, Lu S, Leonard ME,et al. (2016). The type 2 diabetes presumed causal variant within TCF7L2 resides in an element that controls the expression of ACSL5. Diabetologia.
[52] Tuduri E, Lopez M, Dieguez C, Nadal A, Nogueiras R (2016). Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets. Trends Endocrinol Metab, 27:304-318.
[1] Xiaoting Li,Lu Yu,Jing Gao,Xukun Bi,Juhong Zhang,Shiming Xu,Meihui Wang,Mengmeng Chen,Fuyu Qiu,Guosheng Fu. Apelin Ameliorates High Glucose-Induced Downregulation of Connexin 43 via AMPK-Dependent Pathway in Neonatal Rat Cardiomyocytes[J]. A&D, 2018, 9(1): 66-76.
[2] Peng Fangyu, Xie Fang, Muzik Otto. Alteration of Copper Fluxes in Brain Aging: A Longitudinal Study in Rodent Using 64CuCl2-PET/CT[J]. Aging and disease, 2018, 9(1): 109-118.
[3] Xu Yunqi, Wei Xiaobo, Liu Xu, Liao Jinchi, Lin Jiaping, Zhu Cansheng, Meng Xiaochun, Xie Dongsi, Chao Dongman, J Fenoy Albert, Cheng Muhua, Tang Beisha, Zhang Zhuohua, Xia Ying, Wang Qing. Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson's Disease[J]. A&D, 2015, 6(6): 426-436.
[4] Yi Zhou,Rong Fang,Li-Hua Liu,Sheng-Di Chen,Hui-Dong Tang. Clinical Characteristics for the Relationship between Type-2 Diabetes Mellitus and Cognitive Impairment: A Cross-Sectional Study[J]. A&D, 2015, 6(4): 236-244.
[5] Myat Thu Thu Win,Yasuhiko Yamamoto,Seiichi Munesue,Dong Han,Shin-ichi Harada,Hiroshi Yamamoto. Validated Liquid Culture Monitoring System for Lifespan Extension of Caenorhabditis elegans through Genetic and Dietary Manipulations[J]. Aging and Disease, 2013, 4(4): 178-185.
Viewed
Full text


Abstract

Cited

  Shared   
Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail: editorial@aginganddisease.org
Powered by Beijing Magtech Co. Ltd